MCHX heads into its Q1 2026 earnings today with short sellers retreating — a notable setup for a micro-cap AI-powered advertising analytics name priced at $1.59.
The clearest signal in the positioning data is that bears have been stepping away. Short interest has fallen nearly 29% over the past month to just 0.05% of the free float — a level so minimal it carries no real squeeze risk or short-side pressure. Days to cover sits at just one day, confirming shorts are not a meaningful force here. Borrow availability is wide open, with utilization barely registering at 0.2% against a 52-week high of 3.55%, meaning shares to borrow are abundant relative to actual demand. Cost to borrow, at around 21%, looks elevated in isolation but has drifted lower over recent weeks and reflects the illiquid micro-cap nature of the stock rather than any genuine crowding.
Options positioning adds little anxiety to the picture. The put/call ratio has moved slightly below its 20-day average, registering modestly on the call-heavy side — the opposite of a defensive setup. That said, with options volume this thin (the 52-week PCR high is just 0.30), the signal has limited informational weight. The stock itself has slipped 7% on the week and is hovering near $1.59, giving back some of a modest 2.6% gain on the month.
The ownership structure tells the more interesting story heading into the print. Edenbrook Capital holds a dominant 33% of shares, making it far and away the key swing factor in how the stock trades around results. Russell Horowitz, a company co-founder, holds another 13%. Together, these two positions account for nearly half the float — meaning thin trading volume around earnings can move the price sharply on relatively light flow. Edenbrook added shares as recently as March 2025, near current price levels, signalling ongoing conviction at the $1.69–$1.75 range. Analyst coverage has been essentially absent for years; the most recent change in the ORTEX record dates to December 2021, when Roth Capital trimmed its target to $4.00. That target is almost certainly stale relative to where the stock trades today and should not be taken as a current Street view.
Consensus estimates for the quarter point to revenue near $10.9 million with a small net loss. The company has a strong track record of beating expectations — EPS surprise ranks in the 88th percentile across the ORTEX universe — which sets a quiet but meaningful bar. The earnings report will test whether Marchex's AI analytics platform is gaining enough commercial traction to close the gap toward profitability, and whether the cost structure has improved enough to hold Edenbrook's conviction at current prices.
See the live data behind this article on ORTEX.
Open MCHX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
